

WHAT IS CLAIMED IS:

1. An antibody formulation comprising:
 - a. 150 mg/mL anifrolumab;
 - b. 50 mM lysine HCl;
 - c. 130 mM trehalose dihydrate;
 - d. 0.05% polysorbate 80;
 - e. 25 mM histidine/histidine HCl,wherein the formulation is at a pH of 5.9.
2. The antibody formulation of claim 1, wherein the formulation is an injectable formulation suitable for intravenous, subcutaneous, or intramuscular administration.
3. A pre-filled syringe comprising:
 - a. 150 mg/mL anifrolumab;
 - b. 50 mM lysine HCl;
 - c. 130 mM trehalose dihydrate;
 - d. 0.05% polysorbate 80;
 - e. 25 mM histidine/histidine HClwherein the formulation is at a pH of 5.9.